Whole-Exome Sequencing Identifies Mutations in GPR179 Leading to Autosomal-Recessive Complete Congenital Stationary Night Blindness  by Audo, Isabelle et al.
REPORT
Whole-Exome Sequencing Identifies Mutations in GPR179
Leading to Autosomal-Recessive Complete Congenital
Stationary Night Blindness
Isabelle Audo,1,2,3,4,5,39 Kinga Bujakowska,1,2,3,39 Elise Orhan,1,2,3 Charlotte M. Poloschek,6
Sabine Defoort-Dhellemmes,7 Isabelle Drumare,7 Susanne Kohl,8 Tien D. Luu,9 Odile Lecompte,9
Eberhart Zrenner,10 Marie-Elise Lancelot,1,2,3 Aline Antonio,1,2,3,4 Aurore Germain,1,2,3
Christelle Michiels,1,2,3 Claire Audier,1,2,3 Me´lanie Letexier,11 Jean-Paul Saraiva,11 Bart P. Leroy,12,13
Francis L. Munier,14 Saddek Mohand-Saı¨d,1,2,3,4 Birgit Lorenz,15 Christoph Friedburg,15
Markus Preising,15 Ulrich Kellner,16 Agnes B. Renner,17 Veselina Moskova-Doumanova,1,2,3
Wolfgang Berger,18,19,20 Bernd Wissinger,8 Christian P. Hamel,21 Daniel F. Schorderet,22
Elfride De Baere,12 Dror Sharon,23 Eyal Banin,23 Samuel G. Jacobson,24 Dominique Bonneau,25
Xavier Zanlonghi,26 Guylene Le Meur,27 Ingele Casteels,28 Robert Koenekoop,29 Vernon W. Long,30
Francoise Meire,31 Katrina Prescott,32 Thomy de Ravel,33 Ian Simmons,30 Hoan Nguyen,9
He´le`ne Dollfus,34,35 Olivier Poch,9 Thierry Le´veillard,1,2,3 Kim Nguyen-Ba-Charvet,1,2,3
Jose´-Alain Sahel,1,2,3,4,5,36,37 Shomi S. Bhattacharya,1,2,3,5,38 and Christina Zeitz1,2,3,*
Congenital stationary night blindness (CSNB) is a heterogeneous retinal disorder characterized by visual impairment under low
light conditions. This disorder is due to a signal transmission defect from rod photoreceptors to adjacent bipolar cells in the retina.
Two forms can be distinguished clinically, complete CSNB (cCSNB) or incomplete CSNB; the two forms are distinguished on the
basis of the affected signaling pathway. Mutations in NYX, GRM6, and TRPM1, expressed in the outer plexiform layer (OPL) lead to
disruption of the ON-bipolar cell response and have been seen in patients with cCSNB. Whole-exome sequencing in cCSNB patients
lacking mutations in the known genes led to the identification of a homozygous missense mutation (c.1807C>T [p.His603Tyr]) in one
consanguineous autosomal-recessive cCSNB family and a homozygous frameshift mutation in GPR179 (c.278delC [p.Pro93Glnfs*57])
in a simplex male cCSNB patient. Additional screening with Sanger sequencing of 40 patients identified three other cCSNB
patients harboring additional allelic mutations in GPR179. Although, immunhistological studies revealed Gpr179 in the OPL in
wild-type mouse retina, Gpr179 did not colocalize with specific ON-bipolar markers. Interestingly, Gpr179 was highly concentrated
in horizontal cells and Mu¨ller cell endfeet. The involvement of these cells in cCSNB and the specific function of GPR179 remain to
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Congenital stationary night blindness (CSNB) comprises
a group of genetically and clinically heterogeneous retinal
disorders. The associated genes encode proteins that are
confined to the phototransduction cascade or are impor-
tant in retinal signaling from photoreceptors to adjacent
bipolar cells.1 Most of the patients with mutations in
these genes show a typical electrophysiological phenotype
characterized by an electronegative waveform of the dark-
adapted bright flash electroretinogram (ERG), in which
the amplitude of the b-wave is smaller than that of the
a-wave.2 This so-called Schubert-Bornschein-type ERG
response can be divided in two subtypes, incomplete
CSNB ([icCSNB] CSNB2A [MIM 300071], CSNB2B
[MIM 610427]) and complete CSNB ([cCSNB] CSNB1A
[MIM 310500], CSNB1B [MIM 257270] and CSNB1C
[MIM 613216]).3 icCSNB has been characterized by both
a reduced rod b-wave and substantially reduced cone
responses because of both ON- and OFF-bipolar cell
dysfunction, whereas the complete type is associated with
a drastically reduced rod b-wave response because of ON-
bipolar cell dysfunction but largely normal cone b-wave
amplitudes.4 icCSNB has been associated with mutations
in CACNA1F [MIM 300110], CABP4 [MIM 608965], and
CACNA2D4 [MIM 608171], whereas cCSNB has been asso-
ciated with mutations in NYX [MIM 300278], GRM6 [MIM
604096], and TRPM1 [MIM 603576]. So far more than 280
mutations have been identified in these genes by us and
others via direct sequencing of candidate genes (unpub-
lished data) or microarray analysis.5 Prevalence studies
determined that CACNA1F, NYX, and TRPM1 mutations
leading to incomplete and complete CSNB occur more
frequently (unpublished data). Genotyping studies of our
CSNB cohort, comprising 160 patients, reveal that in
~13% of cases mutations in known genes underlying
CSNB were not identified. This is a strong indication that
mutations in other genes remain to be discovered or that
mutations in unscreened regions, that is regulatory
elements and introns, might be involved. Mutations in
many genes leading to CSNB have been identified through
a candidate gene approach by comparing the human
phenotype to similar phenotypes observed in knockout or
naturally occurring animal models.6–13 The bottleneck of
this approach is the size of a cohort and the identification
of the ‘‘right’’ patient harboring the mutation in such
a candidate gene. Novel techniques that use massively
parallel sequencing of all human exons have recently
been successful in identifying mutations in novel genes in
other heterogeneous diseases such as Leber congenital
amaurosis.14,15 To rapidly identify the missing mutations
in our CSNB cohort after whole-exome enrichment (Inte-
graGen, Evry, France), we sequenced four exomes from
a consanguineous autosomal-recessive cCSNB family (that
included parents who were first cousins and two of three
affected children) and from a sporadic male cCSNB patient
of Portuguese origin (Figure S1A and S2, available online,
shows the typical cCSNB ERG of patient CIC02756). One
index patient from each family was previously excluded322 The American Journal of Human Genetics 90, 321–330, Februaryby Sanger sequencing for mutations in GRM6 and TRPM1.
In addition, the sporadic male patient was also excluded
formutations inNYX. Research procedureswere conducted
inaccordancewith institutional guidelines and theDeclara-
tion of Helsinki. Prior to genetic testing, informed consent
was obtained from all patients and their family members.
Ophthalmic examination included best corrected visual
acuity, slit lamp examination, fundoscopy, perimetry, full-
field (ERG) incorporating the International Society for
Clinical Electrophysiology of Vision (ISCEV) standards,16
fundus autofluorescence (FAF), and optical coherence
tomography (OCT) (the extent of investigation depended
on the referring center). Exons of DNA samples were
captured with in-solution enrichment methodology
(SureSelect Human All Exon Kits Version 3, Agilent, Massy,
France) with the company’s biotinylated oligonucleotide
probe library (Human All Exon v3 50 Mb, Agilent). Each
genomic DNA was then sequenced on a sequencer as
paired-end 75 bases (Illumina HISEQ, Illumina, San Diego,
USA). Image analysis and base calling were performed
with Real Time Analysis (RTA) Pipeline version 1.9 with
default parameters (Illumina). The bioinformatic analysis
of sequencing data was based on a pipeline (Consensus
Assessment of Sequence and Variation [CASAVA] 1.8,
Illumina). CASAVA performs alignment, calls the SNPs
basedon the allele calls and read depth, anddetects variants
(SNPs and indels). Genetic variation annotation was per-
formed by an in-house pipeline (IntegraGen) and results
were provided per sample or family in tabulated text files.
After excluding variants observed in dbSNP 132, data were
further filtered to keep only variants in coding and splice
regions that were present in a homozygous state in the
affected children and in a heterozygous state in the parents
from the consanguineous family. This allowed us to reduce
the number of variants from 5,901 indels to 1 and from
66,621 SNPs to 7. The observed deletion represented a
repeat deletion in the penultimate exon of VSIG10 and
was therefore unlikely to be a disease-causing variant.
However, three missense mutations predicted to be prob-
ably or possibly damaging were identified in three different
genes (KIAA0753, CRHR1 [MIM 122561], and GPR179
[G protein-coupled receptor 179]) on chromosome 17.
The p.Arg518Cys variant found in KIAA0753 was consid-
ered unlikely to be disease causing because this arginine
residue is not evolutionarily conserved. On the other
hand, both the p.Arg259Gln substitution in CRHR1 and
the p.His603Tyr in GPR179 affected highly evolutionary
conserved amino acid residues (Figure 1 and Figure S1B).
Interestingly, the other cCSNB patient (CIC02756), also
studiedbywhole-exome sequencing, carried ahomozygous
1 bp deletion, resulting in a frameshift and premature
termination (p.Pro96Glnfs*57) in exon 1 ofGPR179. These
data strongly support the finding that mutations in
GPR179 lead to CSNB found in both families (Table 1).
For the c.1807C>T (p.His603Tyr) mutation, both parents
were found to be heterozygous because the nucleotide A
was read 11 times and 7 times in the father and mother,10, 2012
Figure 1. GPR179 mutations in CSNB.
(A) GPR179 structure containing 11 coding exons (NM_001004334.2). Different mutations identified in cCSNB patients are depicted.
(B) The specific domains for GPR179 were estimated by a prediction program (UniProtKB/Swiss-Prot).respectively, whereas the G was found 13 times and 11
times, respectively (reverse strand). The two affected chil-
dren (patients CIC3308 and CIC04005) showed 26 times
and 14 times the nucleotide A. The c.278delC deletion
detected in the sporadic cCSNB patients was detected 22
times; 20 other reads of unknown type were also indicated.
This might be due to the fact that at this position multiple
Cs are present, and thus different readsmight occur. Sanger
sequencing confirmed the mutations in the index patients
of each family. Both mutations cosegregated with the
phenotype within the respective family (Figure S1A). In
addition, next-generation sequencing data were used to
analyze homozygous regions in the affected siblings
(patients CIC03308 and CIC04005) of the consanguineous
family. The analysis revealed seven major homozygous
regions (>0.5Mb), whichwere exclusively present on chro-
mosome 17. GPR179 was present in the second largest
homozygous region (10.8Mb), whereasCRHR1was present
in a smaller region (1.3 Mb). In the other sporadic cCSNB
patient,GPR179was not present in anymajor homozygous
region; this can be explained by the fact that the parents
were only distant cousins.
We screened 40 CSNB patients (cCSNB and unclassified
CSNB) of various origins and from different clinical centers
in Europe, the United States, Canada, and Israel by using
Sanger sequencing for 27 fragments covering the 11
coding exons and flanking intronic regions of GPR179
(NM_001004334.2). These were amplified by PCR in the
presence of 1.5 mM MgCl2 at an annealing temperature
of 60C. For one of the fragments a specific solution (solu-
tion S, 33, fragment exon 11 m, Hot Fire Polymerase, SolisThe AmericaBioDyne, Tartu, Estonia, and primers; Table S1) was used.
The PCR products were sequenced with a sequencing
mix (BigDyeTerm v1.1 CycleSeq kit, Applied Biosystems,
Courtabœuf, France), analyzed on an automated 48-capil-
lary sequencer (ABI 3730 Genetic analyzer, Applied Bio-
systems), and the results interpreted by applying SeqScape
software (Applied Biosystems). We detected three addi-
tional cCSNB patients who carried compound heterozy-
gous disease-causing mutations (Table 1). The mutation
spectrum identified herein comprises missense, splice-
site, and nonsense mutations and deletions. None of these
changes were present in control chromosomes (R366
chromosomes). For patients whose family members could
be investigated, the mutations cosegregated with the
cCSNB phenotype, and the genotypes were indicative of
an autosomal-recessive mode of inheritance (Table 1 and
Figure S1A). Missense mutations were predicted to be path-
ogenic by PolyPhen and SIFT programs and were also
found to affect evolutionarily conserved amino acid resi-
dues (Figure S1B). On the basis of all of the above evidence,
we conclude that mutations in GPR179 lead to cCSNB.
Interestingly, we found four cCSNB patients with nomuta-
tions in GRM6, TRPM1, NYX, or GPR179, indicating that
mutations in additional genes probably remain to be iden-
tified to explain these cases of cCSNB. In addition, a few
rare variants (Table S2) in GPR179 were identified in
patients screened by Sanger sequencing and were classified
as variants of unknown pathogenicity because only one
mutation was observed or they did not affect conserved
amino acid residues. The frequencies of GPR179 polymor-
phisms found in our patients are provided in Table S3.n Journal of Human Genetics 90, 321–330, February 10, 2012 323
Table 1. Patients with Pathogenic GPR179 Mutations
Patient
Number
Relationship to
Index Patient Sex
Mutations Excluded
in Following Genes Ethnicity and Location Exon
Nucleotide Exchange
(RNA or Protein Effect) Allele State
Control Alleles
(Mutated or WT) Phenotype Index
CIC02756a – male NYX, GRM6, TRPM1 Portuguese-French;
Paris, France
1 c.278delC
(p.Pro93Glnfs*57)
homozygous 0/366 cCSNB, high myopia,
nystagmus, moderate
decreased visual acuity
CIC02757 unaffected father male – 1 c.278delC
(p.Pro93Glnfs*57)
heterozygous
CIC02758 unaffected mother female – 1 c.278delC
(p.Pro93Glnfs*57)
heterozygous
CIC03631 – female GRM6, TRPM1 French; Lille,
France
1, 3 c.376G>C (p.Asp126His),
c.984delC (p.Ser329Leufs*
4)
compound
heterozygous
0/366 and 0/372 cCSNB, high myopia,
strabismus,
micronystagmus
7699 – female GRM6, TRPM1 Tu¨bingen,
Germany
1, 6 c.479_501del
(Leu160Profs*38),
c.1364G>A
(p.Gly455Asp)
compound
heterozygous
0/366 and 0/384 cCSNB, strabismus,
minimal rotational
nystagmus, normal
visual field
7692 unaffected father male – 1 c.479_501del
(p.Leu160Profs*38)
heterozygous
7697 unaffected mother female – 6 c.1364G>A
(p.Gly455Asp)
heterozygous
Y1049 – female GRM6, TRPM1 Lille, France 1, IVS8 c.598C>T (p.Arg200*),
c.1784þ1G>A (r.spl?)
compound
heterozygous
0/378
0/378
cCSNB
Y1166 unaffected father male GRM6, TRPM1 IVS8 c.1784þ1G>A (r.spl) heterozygous
Y1167 unaffected mother female GRM6, TRPM1 1 c.598C>T (p.Arg200*) heterozygous
Y1048 affected sister female GRM6, TRPM1 1, IVS8 c.598C>T (p.Arg200*),
c.1784þ1G>A (r.spl)
compound
heterozygous
26985b,c – male GRM6, TRPM1 Lebanon;
Freiburg, Germany
9 c.1807C>T (p.His603Tyr) homozygous 0/366 cCSNB, left exotropia,
until age of 2 nystagmus
CIC03306 father male – 9 c.1807C>T (p.His603Tyr) heterozygous ERG b-wave were slightly
reduced for high flash
strength
CIC03307 unaffected mother female – 9 c.1807C>T (p.His603Tyr) heterozygous -
CIC03308 affected sister female – 9 c.1807C>T (p.His603Tyr) homozygous cCSNB
CIC04005 affected sister female – 9 c.1807C>T (p.His603Tyr) homozygous cCSNB, visual acuity
reduced
CSNB mutations are annotated according to the recommendation of the Human Genome Variation Society, with nucleotide position þ1 corresponding to the A of the translation-initiation codon ATG in the cDNA
nomenclature RefSeq NM_001004334.2.
a The parents of CIC02756 are far cousins (Figure S1A).
b The diagnostic for GRM6 for this patient was performed in Zurich, Switzerland.
c For this family consanguinity has been reported (Figure S1A).
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To date no information is available on the functional
characterization of GPR179. To predict the protein struc-
ture and the influence of the mutations identified herein,
we created homology models. The human GPR179
sequence (UniProtKB identifier Q6PRD1) was used as a
probe for similarity searches in the UniProtKB database
with the use of the BlastP program.17,18 In total, more
than 100 metazoan sequences (excluding fragments) that
were annotated or predicted as GPR179- or GPR158-like
were highlighted and aligned with a customized version
of the PipeAlign program.19–21 GPR179 codes for a protein
with 2,367 amino acids that can be divided into four main
regions corresponding to a small signal peptide (positions
1–25), the N-terminal extracellular region (position 26-
381), the seven transmembrane (7TM)-spanning region
(position 382-628), and the intracellular C-terminal region
(position 629-2367) (Figure 1B). Sequence analysis pre-
dicted that the N-terminal extracellular region contains
a calcium-binding EGF-like domain (position 278-324),
whereas the C-terminal intracellular region is character-
ized by the presence of a short motif centered on the
sequence CPWE, which is repeated at least 22 times in
the GPR179-related proteins. GPR179 proteins are present
in all vertebrates and are closely related to GPR158 and
GPR158-like proteins. It is noteworthy that the major
differences between GPR179 and the closely related
GPR158 proteins rely on the absence of the calcium-
binding EGF-like domain at the N-terminal part and a
reduced number of CPWE motifs (up to three) in all
GPR158 homologs. Interestingly, three other molecules,
the regulator of G protein signaling 9 (RGS9 [MIM
604067]), the retinal rod rhodopsin-sensitive cGMP
3,5-cyclic phosphodiesterase subunit gamma (PDE6G
[MIM 180073]) and the retinal cone rhodopsin-sensitive
cGMP 3,5-cyclic phosphodiesterase subunit gamma
(PDE6H [MIM 601190]) share the same protein motif
CPWE. These molecules have been implicated in the inhi-
bition of the G protein or amplification of the signal in the
phototransduction cascade. Mutations in those genes lead
to different retinal disorders, including bradyopsia [MIM
608415],22 rod-cone dystrophy [MIM 613582],23 and
cone dystrophy [MIM 610024].24
Based on their seven transmembrane domain regions,
both proteins (GPR179 and GPR158) belong to the gluta-
mate receptor or class CGPCR proteins. This class includes,
among others, metabotropic glutamate receptors (GRMs),
two g-aminobutyric acid B receptor (GABABR), the
calcium-sensing receptor (CASR), the sweet and umami
taste receptors and various orphan receptors.25 The dif-
ferent deletions and the early termination mutation in
GPR179 identified in our patients are located in exons 1
and 3 and are predicted to lead to nonsense-mediated
mRNA decay, which might result in the absence of a
protein product. Alternatively, if a protein is formed,
only the first extracellular part would be present but would
lack all transmembrane domains of GPR179, resulting in
truncated protein (Figure 1B). The missense alterationsThe America(p.Asp126His, p.Gly455Asp, and p.His603Tyr) affect
evolutionarily conserved amino acid residues, which are
predicted to be part of the first extracellular domain,
within the third transmembrane domain, and in the last
extracellular domain (Figure 1B). Multiple alignment anal-
ysis of more than 100metazoan GPR179-related sequences
shows strict conservation of the asparagine at position 126
(Asp126), the glycine at position 455 (Gly455), and the
histidine at position 603 (His603) in vertebrate sequences.
PolyPhen and SIFT programs annotated the three amino
acid substitutions to be possibly pathogenic.26 These
programs use conservation among species and homologs
to predict the pathogenic character of a mutation. In addi-
tion, an inductive logic programming prediction web
server27 predicted p.Gly455Asp and p.His603Tyr to be
pathogenic. This program uses available 3D structures to
predict the influence of a mutation. To date, no model of
the 3D structure of the amino acid residues <300 is avail-
able, therefore the possible pathogenic effect of p.As-
p126His could not be predicted with this program. To
further gain insight into the deleterious effect of the
missense mutations, we generated 3D models of the seven
transmembrane (7TM)-spanning region of the human
wild-type GPR179 and of the two altered proteins
(p.Gly455Asp and p.His603Tyr) by homology modeling
with MODELER software (Figure 2).20 Two known 7TM
templates, the bovine taste receptor (PDB 1F88) and the
squid rhodopsine (PDB 2ZIY), were used to construct the
homology models. For each 3D model construction, ten
homology models were constructed, and the models with
the best normalized discrete optimized potential energy
(DOPE) score were selected.28 The homology 3D models
were visualized and analyzed by means of the SM2PH-
db,28 and figures were constructed with PyMOL software
(version 0.99). Multilevel characterization of the mutants
(physico-chemical changes and structural modifications
induced by the substitution, as well as functional and
structural features related to the mutated position) can be
visualized and analyzed by the MSV3d web server. Struc-
tural analysis of the 3D homology models based on the
squid RHO 3D model (2ZIY) localized the His603 in the
external loop bridging the sixth and seventh transmem-
branes, whereas the Gly455 is localized within the third
transmembrane helix, which is part of a binding pock-
et$(Figures 1B and 2). Our homology model predicts that
the amino acid exchange p.Gly455Asp introduces a long
negatively charged side chain that might point toward
the cavity of the binding pocket. This suggests that the
phenotypic consequences observed for this mutation
might be related to some steric constraints hampering
the normal functioning of the receptor. The steric
constraints in respect to the p.His603Tyr mutation are
less obvious. However, strong conservation across species
and homologs are indicative of an important role for the
histidine at position 603. Although, for the moment, the
3D structure of the amino acid residues <300 of GPR179
is not available, we know from other receptors that the Nn Journal of Human Genetics 90, 321–330, February 10, 2012 325
Figure 2. 3D Model of the Transmem-
brane Region of GPR179
(A) 3D homology model based on the 3D
model of the wild-type squid rhodopsin
(2ZIY). Wild-type Gly455 and His603
residues are indicated in green and the
mutated Asp455 and Tyr603 in orange.
(B) Superimposition of 3D models of
the wild-type residues and the Gly455Asp
alteration (aspartate in orange).terminus of such proteins is important for ligand binding,
and thus the p.Asp126His mutation might be associated
with loss of this binding. On the other hand, the amino
acids that are mutated in our patients also might be impor-
tant for structural properties of the protein in the endo-
plasmic reticulum. Thus a misfolded protein is likely to
be excluded from the strictly regulated transport to the
membrane. Similar findings were observed for mutations
in GRM6, identified in cCSNB patients. Mutated metabo-
tropic glutamate receptor 6 could not reach themembrane,
leading to cCSNB.29 Further functional analysis of the
mutant variants is needed to determine whether these
mutations lead to downregulation of the GPR179 tran-
script, trafficking problems, abolishment of ligand
binding, or interactions with other proteins involved in
signal transmission from photoreceptors to the adjacent
bipolar cells.Figure 3. Indirect Expression Analysis of Gpr179 in rd1 and Wild-Type Mice
Expression of Gpr179 (1459268_at) compared to the expression of Nyx (1446344_at, a know
layer, also implicated in cCSNB) during rod degeneration in the rd1 mouse. Neural retinas
genetic backgrounds47 were hybridized to the mouse genome 430 2.0 array (Affymetrix, Hi
are similar from postnatal day (PND) 5 to PND12. Thereafter, the expression of Gpr179, as w
phenomenon correlates temporally with the loss of rod photoreceptor cells and is likely due
rd1 specimen at this age.
326 The American Journal of Human Genetics 90, 321–330, February 10, 2012As mentioned above, little is
known about the structure and func-
tion of GPR179. However, an EST
profile is available (Unigene database)
and shows a restricted pattern of
expression in the human eye, heart,
and brain. Furthermore, transcrip-
tomic data of whole retina from rd1mice revealed increased expression of GPR179 compared
to the expression in wild-type mice starting from postnatal
day 12 (Figure 3). The rd1 mouse, carrying Pde6b muta-
tions, is a naturally occurring model with progressive rod
photoreceptor degeneration, leading to a complete loss of
all rods by post natal day 36, and preserved inner
retina.30 This would suggest that GPR179 is expressed in
the inner nuclear layer of the retina. Interestingly, Nyx,
another gene with mutations leading to cCSNB, shows
a similar expression profile in the rd1 mouse (Figure 3).
Real-time PCR experiments with two different primer
sets (Table S4) confirmed the expression of GPR179 in
human retina (commercially available cDNA from Clon-
tech, Saint-Germain-en-Laye, France), giving a signal of
DCT ¼ 13.46 (CTGPR179 ¼ 30.03) in relation to beta-actin
(ACTB [MIM 102630]) (CT ACTB ¼ 16.57) (primers Table
S4). Sanger sequencing of the amplified RT-PCR productsn molecule expressed in the inner nuclear
from rd1 and wild-type mice on identical
gh Wycombe, UK). The expression profiles
ell as Nyx, increases in the rd1 retina. This
to the unaffected inner retinal cells in the
Figure 4. Gpr179 Immunohistochemistry on Retinal Sections of
Wild-Type Mice
GPR179 signal (green) in the OPL and ILM double labeled with
other retinal markers (red) were detected in wild-type mice by
confocal microscopy. The scale bar represents 20 mm. The
following abbreviations are used: ONL, outer nuclear layer; OPL,
outer plexiform layer; INL, inner nuclear layer; GCL, ganglion
cell layer; and ILM, inner limiting membrane. Gpr179 did not co-
localize with the presynaptic marker Basoon (A), the ON-bipolar
cell markers Goa (B) and PKCa (C), or with the ganglion cell
labeled with calretinin (D). Some cells in the upper part of INL
were surrounded by specific Gpr179 staining (arrow in A). The
shape and the localizationmight indicate that these cells represent
horizontal cells. Bipolar cell dendrites, stained with PKCa seem to
surround Gpr179 (arrow in C). Calretinin antibody labeled specif-
ically the ganglion cells, and their dendrites did not colocalize
with Gpr179 (arrow in D). Instead, it seems that Gpr179 is highly
concentrated in Mu¨ller cell endfeet (D); similar results have been
previously shown for a potassium channel Kir4.1.31from retinas confirmed the presence of the GPR179 tran-
script. Using the same conditions, we could not detect
the transcript in lymphocytes or HEK293 cells.
We investigated the localization of the Gpr179 protein
in adult mouse retina by immunostaining coronal eye
cryosections with a rabbit polyclonal antibody directed
against GPR179 (Sigma-Aldrich, Saint-Quentin Fallavier,
France). Bound primary antibody was detected with
a secondary antibody (Alexa Fluor 488-conjugated,
Invitrogen, Courtaboeuf, France), and the nuclei were
counterstained (40,6-diamidino-2-phenylindole [DAPI],
Euromedex, Souffelweyersheim, France). Immunofluores-
cence was analyzed with a confocal microscope (FV1000
fluorescent, Olympus, Hamburg, Germany). Gpr179
expression could be detected in the outer plexiform
layer (OPL) and in the inner limiting membrane (ILM),
in close proximity to the ganglion cells (Figure 4, green).
Colocalization studies with a mouse anti-Bassoon (Enzo
Lifescienes, Lyon, France), a specific marker for ribbonThe Americasynapse, excluded a close vicinity between Gpr179 and
presynaptic terminals (Figure 4A). Furthermore, immuno-
staining with mouse antibodies against Goa (Millipore,
Molsheim, France) and PKCa (Sigma-Aldrich), two specific
ON-bipolar markers, demonstrated the absence of colocal-
ization of Gpr179 with these proteins (Figures 4B and 4C).
Instead, Gpr179 appears to be localized in a distinct
compartment within bipolar cells or in other cells, such as
horizontal cells (indicated by the arrow in Figure 4A). Inter-
estingly, bipolar cell dendrites, stained with PKCa, seem to
surround Gpr179 (indicated by the arrow in Figure 4C).
Alternatively, the Gpr179 OPL staining could also be local-
izedwithinMu¨ller cell processespresentwithin this layer. In
addition, a mouse antibody against calretinin (Millipore),
a specific marker for ganglion cells and their dendrites,
was used and did not show colocalization with Gpr179 im-
munostaining (Figure 4D, an example of a ganglion cell
dendrite is marked with an arrow). Instead, Gpr179 was
highly expressed in Mu¨ller cell endfeet at the level of the
ILM; similar results had previously been shown for the
potassium channel Kir4 .1 macromolecular complex.31–33
Therefore, immunolocalization of Gpr179 suggests its
localization in the OPL either in bipolar cells in a cellular
compartment distinct from the synaptic membrane and
cell body, and/or in horizontal cells, and/or in Mu¨ller cell
processes as well as within the Mu¨ller cell endfeet.
The OPL localization of Gpr179 and the same associated
ON-bipolar dysfunction phenotype as for Grm6, Nyx, or
Trpm1 alterations34–38 would suggest that GPR179 is part
of the same transduction pathway and could directly
interact with any of these proteins. However, immunoloc-
alization studies are not in keeping with this hypothesis.
Instead, immunostaining suggests Mu¨ller cell localization
and could place the Gpr179 functional role within these
cells, possibly through the Kir4.1 macromolecular com-
plex. This complex was shown to involve at least the potas-
sium channel Kir4.1, the water channel aquaporin-4
(AQP4), and the dystrophin isoform Dp71. Interestingly,
although Kir4.1 and Aqp4 knockout mice do not show
Schubert- Bornschein ERG abnormalities,39,40 a subset of
dystrophinmutations, responsible for Duchennemuscular
dystrophy (DMD [MIM 310200]) are associated with such
ERG abnormalities.41–44 Therefore, one hypothesis would
be that Gpr179 is part of the Kir4.1 macromolecular
complex. Gpr179 might directly interact with dystrophin
isoforms, and its dysfunction would lead to cCSNB in
a similar mechanism as in DMD. In order to reconcile
the Grm6/Nyx/Trpm1-signaling pathway within bipolar
cells and Gpr179 within Muller cells, one might hypothe-
size that Gpr179 could be involved in an as-yet unknown
interaction between ON-bipolar cells and Mu¨ller cells
that would be essential for ON-bipolar cell depolarization
resulting in b-wave formation. On the other hand, our
immunostaining studies could also suggest specific locali-
zation of Gpr179 within horizontal cells. Therefore,
another hypothesis could be that ON-bipolar cells directly
interact with horizontal cells. Lack of this interaction duen Journal of Human Genetics 90, 321–330, February 10, 2012 327
Figure 5. Genes Underlying CSNB
Different forms of CSNB in human are classified according to their electroretinographic feature, mode of inheritance, clinical phenotype,
and mutated genes. Patients discussed herein show a complete Schubert-Bornschein type of ERG. The following abbreviations are used:
cCSNB, complete CSNB; icCSNB, incomplete CSNB; ar, autosomal recessive; ad, autosomal dominant. Genes are indicated in italics and
underlined. Chromosomal location is given between brackets. The phenotype of patients withmutations in icCSNB is more variable and
can even lead to progressive cone or cone-rod dystrophy.1to Gpr179 dysfunction could lead to the reduced b-wave
observed in patients with cCSNB.
Including the current study, mutations in four genes
(NYX, GRM6, TRPM1, and GPR179) have been implicated
in cCSNB (Figure 5).6,7,10–13,45,46 These genes code for
nyctalopin, metabotropic glutamate receptor 6, transient
receptor potential cation melastatin 1 channel, and G pro-
tein-coupled receptor 179, respectively. All but GPR179
localize postsynaptically to the photoreceptors in the
retina in ON-bipolar cells.35 Further functional studies
will eventually clarify the exact role of this novel protein
within the ON-bipolar cells pathway, which will also
improve our understanding of the overall visual signal
transduction through the retina.Supplemental Data
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